share_log

Are Robust Financials Driving The Recent Rally In Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Stock?

Are Robust Financials Driving The Recent Rally In Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Stock?

穩健的財務狀況是否推動了神經分泌生物科學公司(納斯達克:NBIX)股票的近期反彈?
Simply Wall St ·  01/28 17:59

Neurocrine Biosciences' (NASDAQ:NBIX) stock is up by a considerable 28% over the past three months. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance. In this article, we decided to focus on Neurocrine Biosciences' ROE.

神經分泌生物科學(納斯達克:NBIX)的股票在過去三個月上漲了28%。鑑於市場在長期內獎勵強勁的財務表現,我們想知道在這種情況下是否也是如此。在這篇文章中,我們決定專注於神經分泌生物科學的ROE。

Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders.

股東需要考慮的一個重要因素是股本回報率或ROE,因爲它告訴他們資本是如何有效地再投資的。換句話說,它是一個盈利能力比率,衡量公司股東提供的資本的回報率。

How Do You Calculate Return On Equity?

如何計算股本回報率?

The formula for return on equity is:

股東權益回報率的公式是:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

股東權益回報率 = 凈利潤(來自持續運營)÷ 股東權益

So, based on the above formula, the ROE for Neurocrine Biosciences is:

因此,根據上述公式,神經分泌生物科學的ROE爲:

14% = US$386m ÷ US$2.7b (Based on the trailing twelve months to September 2024).

14% = 38600萬美金 ÷ 27億美金(基於截至2024年9月的過去十二個月)。

The 'return' refers to a company's earnings over the last year. Another way to think of that is that for every $1 worth of equity, the company was able to earn $0.14 in profit.

「回報」指的是公司過去一年的收益。另一種理解方式是,對於每1美元的股本,公司能夠獲得0.14美元的利潤。

What Has ROE Got To Do With Earnings Growth?

ROE與盈利增長有何關係?

So far, we've learned that ROE is a measure of a company's profitability. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.

到目前爲止,我們已經了解了ROE是衡量公司盈利能力的一個指標。我們現在需要評估公司再投資或「保留」未來增長的利潤量,以此給我們提供公司增長潛力的想法。假設其他所有因素保持不變,ROE和利潤保留率越高,相比不具備這些特徵的公司,這些公司的增長率就越高。

Neurocrine Biosciences' Earnings Growth And 14% ROE

神經分泌生物科學的收益增長和14%的ROE

To begin with, Neurocrine Biosciences seems to have a respectable ROE. Further, the company's ROE is similar to the industry average of 18%. This probably goes some way in explaining Neurocrine Biosciences' moderate 12% growth over the past five years amongst other factors.

首先,神經分泌生物科學似乎有着可觀的ROE。此外,該公司的ROE與行業平均的18%相似。這在一定程度上解釋了神經分泌生物科學在過去五年中溫和的12%的增長,其他因素也是如此。

As a next step, we compared Neurocrine Biosciences' net income growth with the industry and were disappointed to see that the company's growth is lower than the industry average growth of 19% in the same period.

作爲下一步,我們將神經分泌生物科學的凈利潤增長與行業進行比較,遺憾地發現該公司的增長低於同期行業平均19%的增長。

big
NasdaqGS:NBIX Past Earnings Growth January 28th 2025
納斯達克GS:NBIX 過去的收益增長 2025年1月28日

Earnings growth is a huge factor in stock valuation. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. Is Neurocrine Biosciences fairly valued compared to other companies? These 3 valuation measures might help you decide.

盈利增長是股票估值的重要因素。投資者需要了解市場是否已經考慮了公司的預期盈利增長(或下降)。這樣,他們就可以知道股票是進入晴朗的沃土還是面臨泥濘的水域。神經分泌生物科學的估值是否合理,與其他公司相比呢?這三項估值指標可能會幫助你做決定。

Is Neurocrine Biosciences Making Efficient Use Of Its Profits?

神經分泌生物科學是否有效利用其利潤?

Neurocrine Biosciences doesn't pay any regular dividends, meaning that all of its profits are being reinvested in the business, which explains the fair bit of earnings growth the company has seen.

神經分泌生物科學不支付任何定期分紅,這意味着它的所有利潤都被再投資於業務中,這解釋了該公司的盈利增長相當可觀的原因。

Conclusion

結論

In total, we are pretty happy with Neurocrine Biosciences' performance. Particularly, we like that the company is reinvesting heavily into its business, and at a high rate of return. As a result, the decent growth in its earnings is not surprising. That being so, the latest analyst forecasts show that the company will continue to see an expansion in its earnings. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company.

總的來說,我們對神經分泌生物科學的表現相當滿意。尤其是,我們喜歡該公司大力再投資於其業務,並且回報率很高。因此,其盈利的不錯增長也就不足爲奇了。儘管如此,最新的分析師預測顯示該公司將繼續看到其盈利的擴張。要了解更多關於該公司的最新分析師預測,請查看該公司的分析師預測可視化。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall ST的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中均沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 318

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。